GSK commitment to Gavi

17 March 2016

GSK reduces the price of Synflorix for Gavi, the Vaccine Alliance

As a demonstration of GSK’s commitment to increase access to vaccines that can help save children’s lives in the world’s poorest countries, we are pleased to offer a further price reduction for our pneumococcal vaccine, Synflorix, to Gavi, the Vaccine Alliance.

With this new offer, we will reduce the tail price of Synflorix to $3.05 USD per dose for Gavi from 2017. This is a 10% price reduction and equates to approximately $1 USD saving per child for the course of this vaccine. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries.

Over the past 16 years, Gavi has played a valuable role in bringing new and under used vaccines to hundreds of millions of children in the world’s poorest countries. GSK is one of the largest contributors of vaccines to Gavi, supplying innovative vaccines for rotavirus, pneumococcal disease and cervical cancer, at significantly reduced prices to help accelerate access in developing countries.

We are keen to continue playing our part in supporting countries as they move from Gavi support due to increased economic wealth towards financing and sustaining their own immunisation programmes.

This is evident in our previous commitment to a ten-year price freeze for countries that graduate from Gavi support. We have also committed that if we identify manufacturing efficiencies, we will to pass savings on to Gavi.

Since we signed an agreement with Gavi in 2010 to provide Synflorix at a deeply discounted price, we have expanded our volume commitments, pledging to deliver 720 million doses of the vaccine up to 2024. Manufacturing at this scale has enabled us to identify incremental cost efficiencies. These have reached a threshold that we feel is meaningful and as a result we are able to offer this further $0.35 USD per dose tail price reduction to Gavi as of 2017 for Synflorix.

We believe this offer will help vaccine price stability for graduating countries, support sustainability of the Gavi model, and enable more children to benefit from national immunisation programmes.